Johnson & Johnson reported second-quarter net income of $5.53 billion, or $2.27 per share, slightly below the $5.54 billion, or $2.29 per share, recorded a year earlier.
Despite the year-over-year dip in absolute terms, the results exceeded Wall Street expectations, driven by robust demand for key pharmaceutical products.
The company also raised its full-year 2026 guidance, signaling strong confidence in its growth trajectory following the recent separation of its consumer health business, Kenvue.
The beat was primarily fueled by the continued commercial momentum of its immunology drug Tremfya and oncology blockbuster Darzalex.
These franchises have become central to J&J’s strategy to offset patent expirations and maintain revenue growth in a competitive pharmaceutical landscape.
The stronger-than-anticipated performance suggests that the company’s focus on high-margin specialty medicines is paying off, even as broader market conditions remain uncertain.
Investors have been closely watching how J&J would perform post-spin-off, with concerns about integration costs and potential cannibalization of resources.